Abstract:BACKGROUNDGlioblastoma multiforme (GBM) is an aggressively malignant brain tumor known for its high recurrence rates and dismal survival outcomes. Despite advancements in surgical and therapeutic strategies, the prognosis for GBM patients remains poor. This study applies proteomic analysis to postoperative GBM tumor specimens to identify molecular markers that could enhance prognosis prediction. Through the analysis of protein expression profiles before and after tumor recurrence, we identified significant alterations in protein pathways via Gene Set Enrichment Analysis (GSEA), highlighting potential biomarkers for disease outcome prediction. METHODSWe employed Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH-MS) proteomics to analyze protein samples from both primary and recurrent GBM patients. Gene Set Enrichment Analysis (GSEA) was utilized to compare protein expression profiles and discern significantly altered pathways. RESULTSAnalysis revealed 778 differentially expressed proteins (DEPs), with notable alterations in pathways such as glycolysis, interleukin signaling, and MAPK signaling. Proteins such as TOLLIP, ENO1, and ITGA2B emerged as potential prognostic markers. Validation through an online tumor prognostic analysis platform (ToPP), integrated with The Cancer Genome Atlas (TCGA) data, facilitated the development of a prognostic risk score model. This model effectively categorized patients into high and low-risk groups based on their protein expression profiles, enhancing the prediction of patient outcomes. The proteins and pathways identified offer new insights into the molecular dynamics of GBM postoperatively. The association between protein expression profiles and patient prognosis underscores the potential of these markers in developing customized therapeutic strategies. Additionally, the prognostic risk score model serves as a valuable tool for improving prognostic accuracy and could guide personalized treatment plans. CONCLUSIONProteomic profiling of GBM tumors significantly contributes to uncovering the molecular mechanisms driving this aggressive cancer and facilitates the development of dependable prognostic tools. These findings not only affirm the critical role of proteomics in cancer research but also advance personalized medicine strategies in GBM management.

Increased Expression of the 58-Kd Microspherule Protein (MSP58) is Correlated with Poor Prognosis in Glioma Patients

Polymeric Immunoglobulin Receptor Expression Is Predictive Of Poor Prognosis In Glioma Patients

Polymeric Immunoglobulin Receptor Expression is Predictive of Poor Prognosis in Glioma Patients.

Expression of MSP58 in human colorectal cancer and its correlation with prognosis

Skp2 protein expression in gliomas and its correlation with malignancy of gliomas and prognosis in the patients

Expression of p57~(kip2) and cyclin D1 in human glioma and its clinical significance

Correlation of Low SLC22A18 Expression with Poor Prognosis in Patients with Glioma.

Expression and Clinical Significance of P57kip2 and P16 in Human Glioma

Expression of High-Mobility Group AT-hook Protein 2 and Its Prognostic Significance in Malignant Gliomas.

Expressions of p57kip2 and p21cip1 in human glioma and their clinical significance

Cnsc-08. Prognostic Biomarker Discovery Through Proteomic Analysis Of Glioblastoma Multiforme

The Correlation between Aberrant Promoter Methylation of MGMT and Immunohistochemical Expression with Clinical Prognosis in Glioblastoma Multiforme

Overexpression of Cell-Surface Marker SLC16A1 Shortened Survival in Human High-Grade Gliomas

High myosin binding protein H expression predicts poor prognosis in glioma patients

Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas.

The Clinical Significance of MMP-2,VEGF and P16 Expression in Human Glioma

The Correlation of the Expression of MGMT and P53 in Human Brain Gliomas with Tumor Grade or Prognosis

Analysis of CD137L and IL-17 Expression in Tumor Tissue As Prognostic Indicators for Gliblastoma.

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Decreased Expression of PACSIN1 in Brain Glioma Samples Predicts Poor Prognosis

MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients